PLENARY VI: THE CLINICAL REALITY AND PROMISE OF CELL AND GENE THERAPIES

Sponsored By 

Plenary Speaker(s)

• 

  Robert Coppes, PhD (he/him/his)

  Biomedical Sciences and Radiation Oncology
  University Medical Center Groningen, Netherlands
• 

  Michael Lai, PhD (he/him/his)

  HeartWorks, USA
• 

  Cristiana Pires, PharmD, PhD

  Asgard Therapeutics, Sweden
• 

  Catherine Priest, PhD (she/her/hers)

  Neurona Therapeutics, USA

Speaker(s)

• 

  Mikael Rydberg

  Patient Advocate, Sweden

Hear from invited speakers from the various realms of regenerative medicine: ESC- and iPSC-derived cell therapies, gene therapies, and in situ reprogramming.

Presentations:

• A PHASE I/II CLINICAL TRIAL OF NRTX-1001 INHIBITORY INTERNEURON CELL THERAPY FOR DRUG-REFRACTORY FOCAL EPILEPSY
  

  Plenary Speaker: Catherine Priest, PhD (she/her/hers) – Neurona Therapeutics
• SALIVARY GLAND ORGANOIDS TO TREATMENT RADIOTHERAPY INDUCED XEROSTOMIA
  

  Plenary Speaker: Robert P. Coppes, PhD (he/him/his) – University Medical Center Groningen
• IN VIVO DIRECT REPROGRAMMING OF TUMOR CELLS TO DENDRITIC CELLS AS A NEW CANCER IMMUNOTHERAPY MODALITY
  

  Plenary Speaker: Cristiana F. Pires, PharmD, PhD – Asgard Therapeutics
• PATIENT ADVOCATE
  

  Speaker: Mikael Rydberg – Patient Advocate
• AUTOLOGOUS IPSC-DERIVED CARDIAC CELL THERAPIES FOR PATIENTS WITH UNIVENTRICULAR CONGENITAL HEART DEFECTS
  

  Plenary Speaker: Michael Lai, PhD (he/him/his) – HeartWorks